-
1دورية أكاديمية
المؤلفون: Mateos Manteca, María Victoria, Hernández, José M., Hernández, Miguel T., Gutiérrez Gutiérrez, Norma Carmen, Palomera, Luis, Fuertes, M., Díaz-Mediavilla, Joaquín, Lahuerta, Juan José, De la Rubia, Javier, Terol, María-José, Sureda, Anna, Bargay, Joan, Ribas, Paz, De Arriba, Felipe, Alegre, Adrian, Oriol, Albert, Carrera, Dolores, García-Laraña, José, García Sanz, Ramón, Bladé, Joan, Prósper, Felipe, Mateo, Gemma, Esseltine, Dixie-Lee, van de Velde, Helgi, San Miguel Izquierdo, Jesús Fernando
مصطلحات موضوعية: Mieloma múltiple, Disease-Free Survival, Immunophenotyping, Aged, Boronic Acids, Humans, Pyrazines, Melphalan, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Multiple Myeloma, Maximum Tolerated Dose, Cohort Studies, Prednisone, protocolos de quimioterapia antineoplásica combinada, humanos, anciano, supervivencia sin enfermedad, prednisona, inmunofenotipificación, ácidos borónicos, dosis máxima tolerada, estudios de cohortes, antineoplásicos, piracinas, melfalán
العلاقة: https://doi.org/10.1182/blood-2006-04-019778Test; Mateos, M. V., Hernández, J. M., Hernández, M. T., Gutiérrez, N. C., Palomera, L., Fuertes, M., . & Miguel, J. F. S. (2006). Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 108(7), 2165-2172. https://doi.org/10.1182/blood-2006-04-019778Test; http://hdl.handle.net/10366/154234Test
-
2
المؤلفون: Anne Banos, Michel Attal, Salomon Manier, Christine Chen, Jin Lu, Javier de la Rubia, Andrew Belch, Michele Cavo, Angela Dispenzieri, Mourad Tiab, John Catalano, Guang Chen, Lugui Qiu, Aurore Perrot, Je-Jung Lee, Katja Weisel, Hervé Avet-Loiseau, Vanessa Houck, Philippe Moreau, Murielle Roussel, Thierry Facon, Nizar J. Bahlis, Heinz Ludwig, Kenneth C. Anderson, Antonello Pinto, Catarina Geraldes, Xavier Leleu, Bertrand Arnulf, Annette Ervin-Haynes, Albert Oriol, Lotfi Benboubker, Meletios A. Dimopoulos, Daniel Binder, Eileen M Boyle, Cyrille Hulin, Darrell White, Jamie D. Cavenagh, Michel Delforge, Mohamad Mohty
المساهمون: Facon, Thierry, Dimopoulos, Meletios A, Dispenzieri, Angela, Catalano, John V, Belch, Andrew, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar J, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie D, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, White, Darell, Binder, Daniel, Jin, Lu, Anderson, Kenneth C, Moreau, Philippe, Attal, Michel, Perrot, Aurore, Arnulf, Bertrand, Qiu, Lugui, Roussel, Murielle, Boyle, Eileen, Manier, Salomon, Mohty, Mohamad, Avet-Loiseau, Herve, Leleu, Xavier, Ervin-Haynes, Annette, Chen, Guang, Houck, Vanessa, Benboubker, Lotfi, Hulin, Cyrille
المصدر: BLOOD
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujolمصطلحات موضوعية: Melphalan, medicine.medical_specialty, Clinical Trials and Observations, Immunology, Urology, Antineoplastic Agents, Biochemistry, 03 medical and health sciences, 0302 clinical medicine, newly diagnosed multiple myeloma, medicine, Clinical endpoint, Humans, Progression-free survival, Survival analysis, Lenalidomide, business.industry, Hazard ratio, Cell Biology, Hematology, Survival Analysis, Progression-Free Survival, Surgery, Thalidomide, Transplantation, Treatment Outcome, 030220 oncology & carcinogenesis, Multiple Myeloma, business, 030215 immunology, medicine.drug
وصف الملف: ELETTRONICO
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e45bdb9fa36b02c60169dd625982ca3Test
https://doi.org/10.1182/blood-2017-07-795047Test